<?xml version='1.0' encoding='utf-8'?>
<document id="27503645"><sentence text="Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine."><entity charOffset="151-163" id="DDI-PubMed.27503645.s1.e0" text="Dolutegravir" /><entity charOffset="167-175" id="DDI-PubMed.27503645.s1.e1" text="Abacavir" /><entity charOffset="181-191" id="DDI-PubMed.27503645.s1.e2" text="Lamivudine" /><pair ddi="false" e1="DDI-PubMed.27503645.s1.e0" e2="DDI-PubMed.27503645.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s1.e0" e2="DDI-PubMed.27503645.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s1.e0" e2="DDI-PubMed.27503645.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s1.e1" e2="DDI-PubMed.27503645.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s1.e1" e2="DDI-PubMed.27503645.s1.e2" /></sentence><sentence text="The direct-acting antiviral regimen of 25 mg ombitasvir-150 mg paritaprevir-100 mg ritonavir once daily (QD) plus 250 mg dasabuvir twice daily (BID) is approved for the treatment of hepatitis C virus genotype 1 infection, including patients coinfected with human immunodeficiency virus"><entity charOffset="83-92" id="DDI-PubMed.27503645.s2.e0" text="ritonavir" /><entity charOffset="121-130" id="DDI-PubMed.27503645.s2.e1" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27503645.s2.e0" e2="DDI-PubMed.27503645.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s2.e0" e2="DDI-PubMed.27503645.s2.e1" /></sentence><sentence text=" This study was performed to evaluate the pharmacokinetic, safety, and tolerability effects of coadministering the regimen of 3 direct-acting antivirals with two antiretroviral therapies (dolutegravir or abacavir plus lamivudine)"><entity charOffset="188-200" id="DDI-PubMed.27503645.s3.e0" text="dolutegravir" /><entity charOffset="204-212" id="DDI-PubMed.27503645.s3.e1" text="abacavir" /><entity charOffset="218-228" id="DDI-PubMed.27503645.s3.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.27503645.s3.e0" e2="DDI-PubMed.27503645.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s3.e0" e2="DDI-PubMed.27503645.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s3.e0" e2="DDI-PubMed.27503645.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s3.e1" e2="DDI-PubMed.27503645.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s3.e1" e2="DDI-PubMed.27503645.s3.e2" /></sentence><sentence text=" Healthy volunteers (n = 24) enrolled in this phase I, single-center, open-label, multiple-dose study received 50 mg dolutegravir QD for 7 days or 300 mg abacavir plus 300 mg lamivudine QD for 4 days, the 3-direct-acting-antiviral regimen for 14 days, followed by the 3-direct-acting-antiviral regimen with dolutegravir or abacavir plus lamivudine for 10 days"><entity charOffset="154-162" id="DDI-PubMed.27503645.s4.e0" text="abacavir" /><entity charOffset="175-185" id="DDI-PubMed.27503645.s4.e1" text="lamivudine" /><entity charOffset="307-319" id="DDI-PubMed.27503645.s4.e2" text="dolutegravir" /><entity charOffset="323-331" id="DDI-PubMed.27503645.s4.e3" text="abacavir" /><entity charOffset="337-347" id="DDI-PubMed.27503645.s4.e4" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e0" e2="DDI-PubMed.27503645.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e0" e2="DDI-PubMed.27503645.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e0" e2="DDI-PubMed.27503645.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e0" e2="DDI-PubMed.27503645.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e0" e2="DDI-PubMed.27503645.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e1" e2="DDI-PubMed.27503645.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e1" e2="DDI-PubMed.27503645.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e1" e2="DDI-PubMed.27503645.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e1" e2="DDI-PubMed.27503645.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e2" e2="DDI-PubMed.27503645.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e2" e2="DDI-PubMed.27503645.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e2" e2="DDI-PubMed.27503645.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e3" e2="DDI-PubMed.27503645.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27503645.s4.e3" e2="DDI-PubMed.27503645.s4.e4" /></sentence><sentence text=" Pharmacokinetic parameters were calculated to compare combination therapy with 3-direct-acting-antiviral or antiretroviral therapy alone, and safety/tolerability were assessed throughout the study" /><sentence text=" Coadministration of the 3-direct-acting-antiviral regimen increased the geometric mean maximum plasma concentration (Cmax) and the area under the curve (AUC) of dolutegravir by 22% (central value ratio [90% confidence intervals], 1"><entity charOffset="162-174" id="DDI-PubMed.27503645.s6.e0" text="dolutegravir" /></sentence><sentence text="219 [1" /><sentence text="153, 1" /><sentence text="288]) and 38% (1" /><sentence text="380 [1" /><sentence text="295, 1" /><sentence text="469]), respectively" /><sentence text=" Abacavir geometric mean Cmax and AUC values decreased by 13% (0" /><sentence text="873 [0" /><sentence text="777, 0" /><sentence text="979]) and 6% (0" /><sentence text="943 [0" /><sentence text="901, 0" /><sentence text="986]), while those for lamivudine decreased by 22% (0"><entity charOffset="23-33" id="DDI-PubMed.27503645.s19.e0" text="lamivudine" /></sentence><sentence text="778 [0" /><sentence text="719, 0" /><sentence text="842]) and 12% (0" /><sentence text="876 [0" /><sentence text="821, 0" /><sentence text="934])" /><sentence text=" For the 3-direct-acting-antiviral regimen, geometric mean Cmax and AUC during coadministration were within 18% of measurements made during administration of the 3-direct-acting-antiviral regimen alone, although trough concentrations for paritaprevir were 34% (0"><entity charOffset="238-250" id="DDI-PubMed.27503645.s26.e0" text="paritaprevir" /></sentence><sentence text="664 [0" /><sentence text="585, 0" /><sentence text="754]) and 27% (0" /><sentence text="729 [0" /><sentence text="627, 0" /><sentence text="847]) lower with dolutegravir and abacavir-lamivudine, respectively"><entity charOffset="17-29" id="DDI-PubMed.27503645.s32.e0" text="dolutegravir" /><entity charOffset="34-42" id="DDI-PubMed.27503645.s32.e1" text="abacavir" /><entity charOffset="43-53" id="DDI-PubMed.27503645.s32.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.27503645.s32.e0" e2="DDI-PubMed.27503645.s32.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s32.e0" e2="DDI-PubMed.27503645.s32.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s32.e0" e2="DDI-PubMed.27503645.s32.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s32.e1" e2="DDI-PubMed.27503645.s32.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s32.e1" e2="DDI-PubMed.27503645.s32.e2" /></sentence><sentence text=" All study treatments were generally well tolerated, with no evidence of increased rates of adverse events during combination administration" /><sentence text=" These data indicate that the 3-direct-acting-antiviral regimen can be administered with dolutegravir or abacavir plus lamivudine without dose adjustment"><entity charOffset="89-101" id="DDI-PubMed.27503645.s34.e0" text="dolutegravir" /><entity charOffset="105-113" id="DDI-PubMed.27503645.s34.e1" text="abacavir" /><entity charOffset="119-129" id="DDI-PubMed.27503645.s34.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.27503645.s34.e0" e2="DDI-PubMed.27503645.s34.e0" /><pair ddi="false" e1="DDI-PubMed.27503645.s34.e0" e2="DDI-PubMed.27503645.s34.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s34.e0" e2="DDI-PubMed.27503645.s34.e2" /><pair ddi="false" e1="DDI-PubMed.27503645.s34.e1" e2="DDI-PubMed.27503645.s34.e1" /><pair ddi="false" e1="DDI-PubMed.27503645.s34.e1" e2="DDI-PubMed.27503645.s34.e2" /></sentence><sentence text="" /></document>